Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes
- PMID: 12012139
- DOI: 10.1007/s00228-001-0407-4
Inhibition of mycophenolic acid glucuronidation by niflumic acid in human liver microsomes
Abstract
Objectives: The first aim of this investigation was to study the variability of mycophenolic acid (MPA) glucuronidation rate in human liver. The second aim was to study the inhibition type of niflumic acid (NA) for MPA glucuronidation in human liver. The third aim was to study the variability of the IC(50) value of NA for MPA glucuronidation in human liver.
Methods: The rate of MPA glucuronidation was measured by employing an assay based on uridine 5'-diphosphate-[U-(14)C]-glucuronic acid (UDPGA), and MPA glucuronide was isolated by means of thin-layer chromatography. The necessary concentration for UDPGA and MPA was 1 mM. The rate of MPA glucuronidation was measured in 50 human liver samples. The inhibition type of NA for MPA glucuronidation was studied in 5 human liver samples. The NA IC(50) value was measured in 27 human liver samples using six concentrations of NA ranging from 1.05 microM to 34 microM.
Results: MPA glucuronidation rate was positively skewed, was not gender regulated and did not correlate with the liver donor's age. The rate of MPA glucuronidation varied 4.8-fold within the 5th and 95th percentiles, with a mean+/-SD and a median of 2.8+/-1.0 nmol/min/mg and 2.5 nmol/min/mg, respectively. The inhibition type of NA for MPA glucuronidation was mixed non-competitive. The Ki value of NA (mean+/-SD) was 15+/-10 microM and, in non-inhibited samples, the K(m) value for MPA was 0.41+/-0.06 mM. The distribution of NA IC(50) value varied 3.3-fold within the 5th and 95th percentiles with a mean+/-SD and a median of 5.6+/-2.1 microM and 5.2 microM, respectively. The distribution of NA IC(50) value did not deviate significantly from normality.
Conclusion: The range of hepatic rate of MPA glucuronidation is narrow relative to those of ethinyloestradiol, testosterone and zidovudine glucuronidation obtained from literature. The Ki value of NA is one order of magnitude lower than the K(m) for MPA in non-inhibited samples. This indicates that the inhibitor affinity for glucuronosyl transferase is greater than that of the substrate. The range of variation of NA IC(50) values is narrow.
Similar articles
-
Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney.Eur J Clin Pharmacol. 2000 Dec;56(9-10):659-64. doi: 10.1007/s002280000227. Eur J Clin Pharmacol. 2000. PMID: 11214772
-
Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices?Exp Toxicol Pathol. 2003 Jun;54(5-6):375-9. doi: 10.1078/0940-2993-00273. Exp Toxicol Pathol. 2003. PMID: 12877348
-
Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.Biochem Pharmacol. 2007 May 15;73(10):1683-91. doi: 10.1016/j.bcp.2007.01.030. Epub 2007 Jan 28. Biochem Pharmacol. 2007. PMID: 17343829
-
Zidovudine glucuronidation in human liver: interindividual variability.Int J Clin Pharmacol Ther. 1996 Aug;34(8):329-34. Int J Clin Pharmacol Ther. 1996. PMID: 8864794
-
In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.Biopharm Drug Dispos. 2006 Jan;27(1):1-6. doi: 10.1002/bdd.475. Biopharm Drug Dispos. 2006. PMID: 16278927
Cited by
-
Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human.Basic Clin Pharmacol Toxicol. 2021 Mar;128(3):511-524. doi: 10.1111/bcpt.13538. Epub 2020 Dec 12. Basic Clin Pharmacol Toxicol. 2021. PMID: 33232579 Free PMC article.
-
Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver.Pharm Res. 2006 Jul;23(7):1502-8. doi: 10.1007/s11095-006-0250-5. Epub 2006 Jun 21. Pharm Res. 2006. PMID: 16783480
-
The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.Clin Pharmacokinet. 2019 Feb;58(2):189-211. doi: 10.1007/s40262-018-0681-2. Clin Pharmacokinet. 2019. PMID: 29862468 Review.
-
A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.Br J Clin Pharmacol. 2006 Oct;62(4):477-84. doi: 10.1111/j.1365-2125.2006.02509.x. Br J Clin Pharmacol. 2006. PMID: 16995869 Free PMC article.
-
Effect of pterostilbene on in vitro drug metabolizing enzyme activity.Saudi Pharm J. 2019 Mar;27(3):406-412. doi: 10.1016/j.jsps.2019.01.001. Epub 2019 Jan 7. Saudi Pharm J. 2019. PMID: 30976185 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources